Recent Updates
Recently added Catalysts
VIR Positive Sentiment

Vir Biotechnology to Present Expanded Phase 2 SOLSTICE Results for Elebsiran and Tobevibart in Hepatitis Delta at AASLD’s The Liver Meeting® 2026

Monday, October 5, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Vir Biotechnology announced it will present expanded results from the Phase 2 SOLSTICE trial at the AASLD The Liver Meeting 2026. The trial evaluates the efficacy of the combination of elebsiran and tobevibart for treating chronic hepatitis delta. This presentation is scheduled for November 5-9, 2026, in Denver, CO.

Market Sentiment Analysis

POSITIVE FACTORS

  • Vir Biotechnology will present expanded results from a Phase 2 trial.
  • The combination therapy shows promise for chronic hepatitis delta.
  • The presentation will occur at a prestigious medical meeting.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+85%
120-day peak, hindsight
Typical move
9.5%
average across 6 past catalysts
Lead asset
Tobevibart
Phase 3 · Viral Hepatitis

Full Press Release Details

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will present data from the Phase 2 SOLSTICE trial evaluating the combination of elebsiran and tobevibart for chronic hepatitis delta at the upcoming American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2026 in Denver, CO, November 5-9, 2026. Efficacy of elebsiran (VIR-2218) and tobevibart (VIR-3434) in participants with chronic hepatitis delta infection: Patterns of HDV R

Frequently Asked Questions

What is the SOLSTICE trial about?

The SOLSTICE trial evaluates the combination of elebsiran and tobevibart for chronic hepatitis delta.

When will the results be presented?

The results will be presented at AASLD The Liver Meeting 2026 from November 5-9, 2026.

Where is the AASLD meeting taking place?

The AASLD The Liver Meeting 2026 will be held in Denver, CO.

What are the drugs involved in the trial?

The trial involves elebsiran (VIR-2218) and tobevibart (VIR-3434).

ShareAdd on Google
Tags: VIR Vir Biotechnology elebsiran tobevibart hepatitis delta AASLD
Last updated: Oct 5, 2026

Biotech snapshot

Cash runway
$529M liquidity · $0M/mo burn
Low dilution risk
Lead asset
TobevibartPhase 3
Viral Hepatitis →

Catalyst track record

+85%
best trade around VIR's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for VIR.

See every catalyst's timing & PoA →